Trastuzumab botidotin
Trastuzumab botidotin is an antibody-drug conjugate (Antibody-Drug Conjugates) targeting HER2, formed by conjugating Trastuzumab (HY-P9907) with Duostatin-5 (HY-145149). Trastuzumab botidotin exerts antitumor effects through microtubule (Microtubule) inhibition and the ADCC mechanism. Trastuzumab botidotin can be used for HER2-positive breast cancer and HER2-positive solid tumors.
For research use only. We do not sell to patients.
- Antibody:
- Linker-Payload:
-
Drug-to-Antibody Ratio:
2
-
Conjugate Type:
site-specific Lysines
- CAS No.: 2699055-12-2
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
All EGFR Isoforms
More
Biological Activity
Description
IC50 & Target
[1]|
HER2 |
In Vitro
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Product Details
-
Antibody
-
Linker-Payload
-
Drug-to-Antibody Ratio
2
-
Conjugate Type
site-specific Lysines
Chemical Information
-
CAS No. 2699055-12-2
-
SMILES
[Trastuzumab botidotin]
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
[2]. Zhang J, et al. Trastuzumab Botidotin Versus Trastuzumab Emtansine in Human Epidermal Growth Factor Receptor 2-Positive Advanced Breast Cancer: A Phase III, Open-Label, Randomized Controlled Trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2026 Sep 11. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Keywords
- Trastuzumab botidotin
- 2699055-12-2
- Antibody-Drug Conjugates (ADCs)
- EGFR
- Microtubule/Tubulin
- Antibody-Drug Conjugates
- ADC
- Epidermal growth factor receptor
- ErbB-1
- HER1
- HER2
- HER2+ solid malignancies
- HER2-positive unresectable/metastatic breast cancer
- antibody-drug conjugate
- duostatin-5
- protease-cleavable linker
- solid tumor xenograft
- trastuzumab emtansine
- tumor growth
- Inhibitor
- inhibitor
- inhibit